Blood biomarkers may have applications in stroke diagnosis, outcome prediction, or treatment. In this article, we provide a focused review on some of the methodological challenges and potential developments of biomarkers in stroke. We review the approaches to the development of a diagnostic blood marker: a candidate marker approach, marker panels, and –omics. Then we examined the role of blood markers to predict recurrent stroke and treatment response in stroke.
KarpetskyT.P.HumphreyR.L.LevyC.C.Influence of renal insufficiency on levels of serum ribonuclease in patients with multiple myeloma. J Natl Cancer Inst1977; 58:875–80.
2.
PalidworG.A.Andrade-NavarroM.A.MLTrends: graphing MEDLINE term usage over time. J Biomed Discov Collab2010; 5:1–6.
3.
AtkinsonA.J.ColburnW.A.DeGruttolaV.G.Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther2001; 69:89–95.
4.
WhiteleyW.TsengM.C.SandercockP.Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke2008; 39:2902–9.
5.
RoystonP.SauerbreiW.Multivariable Modelling: A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Continuous Variables, 1st edn.Chichester, John Riley & Sons Ltd., 2008.
6.
SteyerbergE.W.Clinical Prediction Models. New York, Springer, 2009.
7.
AltmanD.G.VergouweY.RoystonP.MoonsK.G.M.Prognosis and prognostic research: validating a prognostic model. BMJ2009; 338:b605.
8.
LaskowitzD.T.KasnerS.E.SaverJ.RemmelK.S.JauchE.C.Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke2009; 40:77–85.
9.
JinG.ZhouX.WangH.WongS.T.C.The challenges in blood proteomic biomarker discovery; in PhamT. (ed.): Computational Biology. New York, Springer, *2010:273–99.
10.
SidesoE.PapadakisM.WrightC.Assessing the quality and reproducibility of a proteomic platform for clinical stroke biomarker discovery. Transl Stroke Res2010; 1:304–14.
11.
DiamandisE.P.Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst2004; 96:353–6.
12.
RansohoffD.F.Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer2005; 5:142–9.
13.
DiamandisE.P.Cancer biomarkers: can we turn recent failures into success?J Natl Cancer Inst2010; 102:1462–7.
14.
LiottaL.A.PetricoinE.F.Putting the ‘bio’ back into biomarkers: orienting proteomic discovery toward biology and away from the measurement platform. Clin Chem2008; 54:3–5.
15.
JacobsJ.M.AdkinsJ.N.QianW.J.Utilizing human blood plasma for proteomic biomarker discovery. J Proteome Res2005; 4:1073–85.
16.
SharpF.R.JicklingG.C.StamovaB.S.Molecular markers and mechanisms of stroke: RNA studies of blood in animals and humans. J Cereb Blood Flow Metab2011; 31:1513–31.
17.
AlizadehA.A.EisenM.B.DavisR.E.Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature2000; 403:503–11.
18.
TangY.XuH.DuX.Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab2006; 26:1089–102.
19.
StamovaB.XuH.JicklingG.Gene expression profiling of blood for the prediction of ischemic stroke. Stroke2010; 41:2171–7.
20.
BarrT.L.ConleyY.DingJ.Genomic biomarkers and cellular pathways of ischemic stroke by RNA gene expression profiling. Neurology2010; 75:1009–14.
21.
MooreD.F.LiH.JeffriesN.Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation2005; 111:212–21.
22.
JicklingG.C.XuH.StamovaB.Signatures of cardioembolic and large-vessel ischemic stroke. Ann Neurol2010; 68:681–92.
23.
XuH.TangY.LiuD.Z.Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of ischemic stroke. J Cereb Blood Flow Metab2008; 28:1320–8.
24.
CoullA.J.LovettJ.K.RothwellP.M.Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ2004; 328:326.
25.
JohnstonS.C.RothwellP.M.Nguyen-HuynhM.N.Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet2007; 369:283–92.
26.
HlatkyM.A.GreenlandP.ArnettD.K.Criteria for evaluation of novel markers of cardiovascular risk. Circulation2009; 119:2408–16.
27.
Di NapoliM.PapaF.BocolaV.C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke2001; 32:917–24.
28.
WhiteleyW.JacksonC.LewisS.Association of circulating inflammatory markers with recurrent vascular events after stroke: a prospective cohort study. Stroke2011; 42:10–6.
29.
ElkindM.S.TaiW.CoatesK.PaikM.C.SaccoR.L.High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med2006; 166:2073–80.
30.
RothwellP.M.HowardS.C.PowerD.A.Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke2004; 35:2300–5.
31.
PencinaM.J.D'AgostinoR.B.D'AgostinoR.B.VasanR.S.Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med2008; 27:157–72.
32.
VasanR.S.Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation2006; 113:2335–62.
33.
ShahT.CasasJ.P.CooperJ.A.Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol2009; 38:217–31.
34.
SattarN.WelshP.SarwarN.NT-proBNP is associated with coronary heart disease risk in healthy older women but fails to enhance prediction beyond established risk factors: results from the British Women's Heart and Health Study. Atherosclerosis2010; 209:295–9.
35.
CounsellC.DennisM.McDowallM.Predicting functional outcome in acute stroke: comparison of a simple six variable model with other predictive systems and informal clinical prediction. J Neurol Neurosurg Psychiatry2004; 75:401–5.
36.
KonigI.R.ZieglerA.BluhmkiE.Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke2008; 39:1821–6.
37.
WhiteleyW.ChongW.L.SenguptaA.SandercockP.Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke2009; 40:e380–9.
38.
CastellanosM.SobrinoT.PedrazaS.High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology2008; 71:1862–8.
39.
WhiteleyW.WardlawJ.DennisM.The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke2011; 43:86–91.
40.
CastellanosM.SobrinoT.MillanM.Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke2007; 38:1855–9.
41.
PareG.MehtaS.R.YusufS.Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med2010; 363: 1704–14.
42.
BauerT.BoumanH.J.Van WerkumJ.W.FordN.F.Ten BergJnMTaubertD.Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ2011; 343:d4588.
